Nuhad K. Ibrahim

Peer-Reviewed Articles

1. Chen S, Ibrahim NK, Yan Y, Wong ST, Wang H, Wong FC. Complete Metabolic Response on Interim 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. Oncologist 22(5):526-534, 2017. e-Pub 2017. PMID: 28377466.
2. Sneige N, Hess KR, Multani AS, Gong Y, Ibrahim NK. Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study. Cancer 123(7):1115-1123, 2017. e-Pub 2016. PMID: 27893937.
3. Mitri Z, Nanda R, Blackwell K, Costelloe CM, Hood I, Wei C, Brewster AM, Ibrahim NK, Koenig KB, Hortobagyi GN, Van Poznak C, Rimawi MF, Moulder-Thompson S, Translational Breast Cancer Research Consortium. TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis. Clin Cancer Res 22(23):5706-5712, 2016. e-Pub 2016. PMID: 27166393.
4. Arun BK, Gong Y, Liu D, Litton JK, Gutierrez-Barrera AM, Jack Lee J, Vornik L, Ibrahim NK, Cornelison T, Hortobagyi GN, Heckman-Stoddard BM, Koenig KB, Alvarez RR, Murray JL, Valero V, Lippman SM, Brown P, Sneige N. Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. Breast Cancer Res Treat 158(1):67-77, 2016. e-Pub 2016. PMID: 27287781.
5. Heery CR, Ibrahim NK, Arlen PM, Mohebtash M, Murray JL, Koenig K, Madan RA, McMahon S, Marté JL, Steinberg SM, Donahue RN, Grenga I, Jochems C, Farsaci B, Folio L, Schlom J, Gulley JL. Docetaxel alone or in combination with a therapeutic cancer vaccine (PANVAC) in patients with metastatic breast cancer: a randomized clinical trial. JAMA Oncol. e-Pub 2015. PMID: 26291768.
6. Delpech Y, Lousquy R, Rouzier R, Hess K, Coutant C, Barranger E, Esteva FJ, Ueno NT, Pusztai L, Ibrahim NK. Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. Br J Cancer, 2015. e-Pub 2015. PMID: 26393887.
7. Yust-Katz S, Garciarena P, Liu D, Ibrahim NK, Penas-Prado M, Groves M. Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD but not survival. J Neurooncol 114:229-235, 2013.
8. Kelly CM, Green MC, Broglio K, Thomas ES, Brewster AM, Valero V, Ibrahim NK, Gonzalez-Angulo AM, Booser DJ, Walters RS, Hunt KK, Hortobagyi GN, Buzdar AU. Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol 30(9):930-5, 2012. e-Pub 2012. PMID: 22331946.
9. Gerber DE, Stopeck AT, Wong L, Rosen LS, Thorpe PE, Shan JS, Ibrahim NK. Phase I safety and pharmacokinetic study of bavituximab, a chimeric phosphatidylserine-targeting monoclonal antibody, in patients with advanced solid tumors. Clin Cancer Res 17(21):1-9, 2011. e-Pub 2011. PMID: 21989064.
10. Ibrahim NK, Yariz KO, Bondarenko I, Manikhas A, Semiglazov V, Alyasova A, Komisarenko V, Shparyk Y, Murray JL, Jones D, Senderovich S, Chau A, Erlandsson F, Acton G, Pegram M. Randomized phase II trial of letrozole plus anti-MUC1 antibody AS1402 in hormone receptor-positive locally advanced or metastatic breast cancer. Clin Cancer Res 17(21):6822-30, 2011. e-Pub 2011. PMID: 21878535.
11. Finn RS, Bengala C, Ibrahim N, Roché H, Sparano J, Strauss LC, Fairchild J, Sy O, Goldstein LJ. Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. Clin Cancer Res 17(21):6905-13, 2011. e-Pub 2011. PMID: 22028489.
12. Hatzis C, Pusztai L, Valero V, Booser DJ, Esserman L, Lluch A, Vidaurre T, Holmes F, Souchon E, Wang H, Martin M, Cotrina J, Gomez H, Hubbard R, Chacón JI, Ferrer-Lozano J, Dyer R, Buxton M, Gong Y, Wu Y, Ibrahim N, Andreopoulou E, Ueno NT, Hunt K, Yang W, Nazario A, DeMichele A, O'Shaughnessy J, Hortobagyi GN, Symmans WF. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA 305(18):1873-81, 2011. PMID: 21558518.
13. Miles D, Roché H, Martin M, Perren TJ, Cameron DA, Glaspy J, Dodwell D, Parker J, Mayordomo J, Tres A, Murray JL, Ibrahim NK, Theratope® Study Group. Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer. Oncologist 16(8):1092-1100, 2011. e-Pub 2011. PMID: 21572124.
14. Arun BK, Dhinghra K, Valero V, Kau SW, Broglio K, Booser D, Guerra L, Yin G, Walters R, Sahin A, Ibrahim N, Buzdar AU, Frye D, Sneige N, Strom E, Ross M, Theriault RL, Vadhan-Raj S, Hortobagyi GN. Phase III Randomized Trial of Dose Intensive Neoadjuvant Chemotherapy with or Without G-CSF in Locally Advanced Breast Cancer: Long-Term Results. Oncologist 16(11):1527-34, 2011. e-Pub 2011. PMID: 22042783.
15. Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-Figueroa LJ, Souchon E, Coutant C, Doimi FD, Ibrahim NK, Gong Y, Hortobagyi GN, Hess KR, Symmans WF, Pusztai L. Evaluation of a 30-gene Paclitaxel, Fluorouracil, Doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res 16(21):5351-61, 2010. e-Pub 2010. PMID: 20829329.
16. Hortobagyi GN, Young RR, Karwal M, Ibrahim NK, Hermann R, Murray JL, Watkins SP, Gore I. A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer. Cancer 116(10):2301-6, 2010. e-Pub 2010. PMID: 20225231.
17. Graesslin O, Abdulkarim BS, Coutant C, Huguet F, Gabos Z, Hsu L, Marpeau O, Uzan S, Pusztai L, Strom EA, Hortobagyi GN, Rouzier R, Ibrahim NK. Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol 28(12):2032-7, 2010. e-Pub 2010. PMID: 20308667.
18. Royer B, Yin W, Pegram M, Ibrahim N, Villanueva C, Mir D, Erlandsson F, Pivot X. Population pharmacokinetics of the humanised monoclonal antibody, HuHMFG1 (AS1402), derived from a phase I study on breast cancer. Br J Cancer 102(5):827-32, 2010. e-Pub 2010. PMID: 20160731.
19. Ibrahim NK. Ixabepilone Development Across the Breast Cancer Continuum: A Paradigm Shift. Cancer Manag Res 2:169-179, 2010. e-Pub 2010. PMID: 21188108.
20. Pegram MD, Borges V, Ibrahim N, Fuloria J, Shapiro C, Perez S, Wang K, Schaedeli Stark F, Courtenay Luck N. Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Res 11(5):R73, 2009. e-Pub 2009. PMID: 19811637.
21. Estephan F, Valero V, Esteva FJ, Mejia JA, Frye DK, Ibrahim NK. Phase I Study of Prolonged-infusion Gemcitabine Combined with Cyclophosphamide in Patients with Metastatic Carcinoma of the Breast: Tolerability of an Optimal Dose Schedule. Oncology 77(1):63-70, 2009. e-Pub 2009. PMID: 19556811.
22. Shumway NM, Ibrahim N, Ponniah S, Peoples GE, Murray JL. Therapeutic Breast Cancer Vaccines: A New Strategy for Early-Stage Disease. BioDrugs 23(5):277-87, 2009. PMID: 19754218.
23. Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, Aldape KD, Yu TK, Hortobagyi GN, Gonzalez-Angulo AM. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 19(7):1242-8, 2008. e-Pub 2008. PMID: 18334512.
24. Kaur H, Loyer EM, David CL, Sawaf H, DuBrow RA, Ibrahim NK. Radiologic findings in taxane induced colitis. Eur J Radiol 66(1):75-8, 2008. e-Pub 2007. PMID: 17553645.
25. Buzdar AU, Valero V, Ibrahim NK, Francis D, Broglio KR, Theriault RL, Pusztai L, Green MC, Singletary SE, Hunt KK, Sahin AA, Esteva F, Symmans WF, Ewer MS, Buchholz TA, Hortobagyi GN. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 13(1):228-33, 2007. PMID: 17200359.
26. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gomez HL, Hortobagyi GN, Pusztai L. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24:4236-44, 2006. PMID: 16896004.
27. Motwani SB, Strom EA, Schechter NR, Butler CE, Lee GK, Langstein HN, Kronowitz SJ, Meric-Bernstam F, Ibrahim NK, Buchholz TA. The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys 66(1):76-82, 2006. e-Pub 2006. PMID: 16765534.
28. Altundag K, Ibrahim NK. Aromatase inhibitors in breast cancer: an overview. Oncologist 11(6):553-62, 2006. PMID: 16794235.
29. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, Cristofanilli M, Booser DJ, Pusztai L, Rivera E, Theriault RL, Carter C, Frye D, Hunt KK, Symmans WF, Strom EA, Sahin AA, Sikov W, Hortobagyi GN. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol 23(25):5983-92, 2005. PMID: 16087943.
30. Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC, Nair MK, Bhar P, Desai N, Hortobagyi GN. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23:6019-26, 2005. PMID: 16135470.
31. Pusztai L, Wagner P, Ibrahim N, Rivera E, Theriault R, Booser D, Symmans FW, Wong F, Blumenschein G, Fleming DR, Rouzier R, Boniface G, Hortobagyi GN. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104(4):682-91, 2005. PMID: 15986399.
32. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11(16):5678-85, 2005. PMID: 16115903.
33. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, Pusztai L, Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, Sahin AA, Ewer MS, Buchholz TA, Berry D, Hortobagyi GN. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23:3676-85, 2005. PMID: 15738535.
34. Li Z, Ibrahim NK, Wathen JK, Wang M, Mante Menchu RP, Valero V, Theriault R, Buzdar AU, Hortobagyi GN. Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. Cancer 101(7):1508-13, 2004. PMID: 15378497.
35. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K, Lecocke M, Metivier J, Booser D, Ibrahim N, Valero V, Royce M, Arun B, Whitman G, Ross J, Sneige N, Hortobagyi GN, Pusztai L. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol 22(12):2284-93, 2004. PMID: 15136595.
36. Pusztai L, Mendoza TR, Reuben JM, Martinez MM, Willey JS, Lara J, Syed A, Fritsche HA, Bruera E, Booser D, Valero V, Arun B, Ibrahim N, Rivera E, Royce M, Cleeland CS, Hortobagyi GN. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 25(3):94-102, 2004. PMID: 14698135.
37. Morandi P, Rouzier R, Altundag K, Buzdar A, Theriault R, Arun B, Booser D, Cristofanilli M, Esteva F, Gonzalez-Angulo A, Giordano S, Green M, Gwyn K, Ibrahim N, Murray J, Pusztai L, Rivera E, Thomas E, Valero V, Walters R, Bast R, Bevers T, Brewster A, Buchholz T, McNeese M, Strom E, Hortobagyi GN. The Role of Aromatase Inhibitors in the Adjuvant Treatment of Breast Cancer: MD Anderson Cancer Center Evidence Based Approach. Cancer 101 (7):1482-1489, 2004.
38. Trent JC, Valero V, Booser DJ, Esparza-Guerra LT, Ibrahim N, Rahman Z, Vernillet L, Patel S, David CL, Murray JL, Cristofanilli M, Hortobagyi GN. A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer. Clin Cancer Res 9(7):2426-34, 2003. PMID: 12855614.
39. Symmans WF, Ayers M, Clark EA, Stec J, Hess KR, Sneige N, Buchholz TA, Krishnamurthy S, Ibrahim NK, Buzdar AU, Theriault RL, Rosales MF, Thomas ES, Gwyn KM, Green MC, Syed AR, Hortobagyi GN, Pusztai L. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer 97(12):2960-71, 2003. PMID: 12784330.
40. Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O'Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 21(6):1167-73, 2003. PMID: 12637486.
41. Saab GA, Ibrahim N, Azouri N. Efficacy of continuous high-dose metoclopramide in patients receiving daily cisplatin infusions. Cancer Treat Rep 71(10):979-80, 1987. PMID: 3652059.
42. Salem P, el-Hashimi L, Anaissie E, Geha S, Habboubi N, Ibrahim N, Khalyl M, Allam C. Primary small intestinal lymphoma in adults. A comparative study of IPSID versus non-IPSID in the Middle East. Cancer 59(9):1670-6, 1987. PMID: 3828967.
43. Salem P, Anaissie E, Allam C, Geha S, Hashimi L, Ibrahim N, Jabbour J, Habboubi N, Khalyl M. Non-Hodgkin's lymphomas in the Middle East. A study of 417 patients with emphasis on special features. Cancer 58(5):1162-6, 1986. PMID: 3731043.

Invited Articles

1. Hortobagyi GN, Holmes FA, Ibrahim N, Champlin R, Buzdar AU. The University of Texas M.D. Anderson Cancer Center experience with paclitaxel in breast cancer. Semin Oncol 24 (Suppl 3):30-33, 1997. PMID: 9071338.

Abstracts

1. Lin NU, Stein A, Nicholas A, Fung AM, Kumthekar P, Ibrahim NK, Pegram MD. Planned interim analysis of PATRICIA: An open-label, single-arm, phase II study of pertuzumab (P) with high-dose trastuzumab (H) for the treatment of central nervous system (CNS) progression post radiotherapy (RT) in patients (pts) with HER2-positive metastatic breast cancer (MBC). 2017 ASCO Annual Meeting, 2017.
2. Tripathy D, Tolaney SM, Seidman AD, Anders CK, Ibrahim NK, Rugo HS, Twelves C, Dieras V, Müller V, Hannah A, Tagliaferri M, Cortés J. ATTAIN: Phase 3 study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC). 2017 ASCO Annual Meeting, 2017.
3. P. Kumthekar, SC. Tang, A. Brenner, S. Kesari, C. Anders, J. Carrillo, P. Chalasani, P. Kabos, M. Ahluwalia, Ibrahim N. A Phase II Study of ANG1005, a novel BBB/BCB Penetratant Taxane in Patients with Recurrent Brain Metastases and Leptomeningeal Carcinomatosis from Breast Cancer. EANO, 2016.
4. Tang S-C, Kumthekar P, Brenner AJ, Kesari S, D. Piccioni D, Anders CK, Carillo JA, Chalasani P,Kabos P, Puhalla SL, Garcia A, Tkaczuk K. Ahluwalia MS, Lakhani N, Ibrahim NK . ANG1005, a novel peptide-paclitaxel conjugate crosses the BBB and shows activity in patients with recurrent CNS metastasis from breast cancer, results from a Phase II Clinical Study. European Society for Medical Oncology, 2016.
5. Chen S, Ibrahim NK, Wong S, Wang H, Wong FC. Prognostic value of metabolic complete response on 18F-FDG PET/CT in stage II or III breast cancer patients. Proc. from Socitey of Nuclear Medicine and Molecular Imaging 2015, 2015.
6. Ibrahim N, Abdulkarim B, Huguet F, Gabos Z, Hsu L, Marpeau O, Uzan S, Pusztai L, Strom E, Hortobagyi GN, Rouzier R. A nomogram to predict subsequent brain metastasis in metastatic breast cancer (MBC) patients. European Society for Medical Oncology (ESMO), 2008.

Book Chapters

1. Shonka NA, Ibrahim NKb, Groves MD. Management of central nervous system metastases in breast cancer. In: Advanced Therapy of Breast Disease, 2012.
2. Barcenas CH, Ibrahim NK. Chemotherapy-Induced Colitis. In: Colitis. Intech, 2012.
3. Matrana MR, Ibrahim NK. Breast cancer metastasis to the central nervous system. In: Tumors of the Central Nervous System. Springer, 35-49, 2012.